Suppurative thrombophlebitis medical therapy

Suppurative thrombophlebitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Suppurative thrombophlebitis from other Diseases
Risk Factors
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Case Studies
Case #1
Suppurative thrombophlebitis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Suppurative thrombophlebitis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Suppurative thrombophlebitis medical therapy
CDC on Suppurative thrombophlebitis medical therapy
Suppurative thrombophlebitis medical therapy in the news
Blogs on Suppurative thrombophlebitis medical therapy
Directions to Hospitals Treating Suppurative thrombophlebitis
Risk calculators and risk factors for Suppurative thrombophlebitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The mainstay of therapy for suppurative thrombophlebitis is antimicrobial therapy. Empiric therapy includes anti-staphylococcal antibiotics plus antibiotics with coverage against enterobacteriaceae. The benefit of pharmacologic anticoagulation is uncertain in suppurative thrombophlebitis and is not routinely recommended.

Medical Therapy

Antimicrobial Regimens

• Treatment of suppurative thrombophlebitis

• 1. Bacterial pathogens

• 1.1 Gram-positive bacilli

• 1.1.1 Staphylococcus aureus

• 1.1.1.1 Methicillin-sensitive

• Preferred regimen: Nafcillin 2 g IV q4h OR Oxacillin 2 g IV q4h
• Alternative regimen: Cefazolin 2 g IV q8h OR Vancomycin 15 mg/kg q12h (trough levels 15-20 mcg/ml)

• 1.1.1.2 Methicillin-resistant

• Preferred regimen: Vancomycin 15 mg/kg q12h (trough levels 15-20 mcg/ml)
• Alternative regimen (1): Daptomycin 6-8 mg/kg/day IV q24h OR Linezolid 600 mg IV q12h
• Alternative regimen (2): Trimethoprim-sulfamethoxazole 20 mg TMP/kg/day IV q6hr

• 1.1.2 Coagulase-negative staphylococci

• 1.1.2.1 Methicillin-sensitive

• Preferred regimen: Nafcillin 2 g IV q4h OR Oxacillin 2 g IV q4h
• Alternative regimen: Cefazolin 2 g IV q8h OR Vancomycin 15 mg/kg q12h (trough levels 15-20 mcg/ml)

• 1.1.2.2 Methicillin-resistant

• Preferred regimen: Vancomycin 15 mg/kg q12h (trough levels 15-20 mcg/ml)
• Alternative regimen: Daptomycin 6-8 mg/kg/day IV q24h OR Linezolid 600 mg IV q12h OR Quinupristin/Dalfopristin 7.5 mg/kg IV q8h
• Note: Linezolid-resistant strains have been reported

• 1.1.3 Enterococcus faecalis & Enterococcus faecium

• 1.1.3.1 Ampicillin-sensitive

• Preferred regimen: Ampicillin 2 g IV q4-6h ± Gentamicin 1 mg/kg IV q8h
• Alternative regimen: Vancomycin 15 mg/kg q12h (trough levels 15-20 mcg/ml)

• 1.1.3.2 Ampicillin-resistant & Vancomycin-sensitive

• Preferred regimen: Ampicillin 2 g IV q4-6h AND Gentamicin 1 mg/kg IV q8h
• Alternative regimen: Daptomycin 6-8 mg/kg/day IV q24h OR Linezolid 600 mg IV q12h

• 1.1.3.3 Ampicillin-resistant & Vancomycin-resistant

• Preferred regimen: Daptomycin 6-8 mg/kg/day IV q24h OR Linezolid 600 mg IV q12h
• Alternative regimen: Quinupristin/Dalfopristin 7.5 mg/kg IV q8h
• Note: Quinupristin/Dalfopristin is not effective against E. faecalis

• 1.2 Gram-negative bacilli

• 1.2.1 Escherichia coli & Klebsiella spp.

• 1.2.1.1 ESBL negative

• Preferred regimen: Ceftriaxone 1-2 g IV q24h
• Alternative regimen: Ciprofloxacin 400 mg IV q8-12h OR Aztreonam 1-2 g IV q6-12h (maximum dose 8 g/day)

• 1.2.1.2 ESBL positive

• Preferred regimen: Ertapenem 1 g IV/IM q24h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h OR Doripenem 500 mg IV q8h
• Alternative regimen: Ciprofloxacin 400 mg IV q8-12h OR Aztreonam 1-2 g IV q6-12h (maximum dose 8 g/day)

• 1.2.2 Enterobacter spp. & Serratia marcescens

• Preferred regimen: Ertapenem 1 g IV/IM q24h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h
• Alternative regimen: Cefepime 1-2 g IV q8-12h OR Ciprofloxacin 400 mg IV q8-12h

• 1.2.3 Acinetobacter spp.

• Preferred regimen: Ampicillin-Sulbactam 1.5-3 g IV/IM q6h OR Ertapenem 1 g IV/IM q24h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h OR Doripenem 500 mg IV q8h

• 1.2.4 Stenotrophomonas maltophilia

• Preferred regimen: Trimethoprim-Sulfamethoxazole 3–5 PO/IV mg/kg q8h
• Alternative regimen: Ticarcillin-Clavulanate 3.1 g IV q4-6h

• 1.2.5 Pseudomonas aeruginosa

• Preferred regimen: Cefepime 1-2 g IV q8-12h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h OR Amikacin 15 mg/kg IV q24h or Tobramycin 5–7 mg/kg IV q24h

• 1.2.6 Burkholderia cepacia

• Preferred regimen: Trimethoprim-Sulfamethoxazole 3–5 PO/IV mg/kg q8h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h

• 2. Fungal pathogens

• 2.1 Candida spp.

• Preferred regimen (1): Caspofungin 70 mg IV single dose THEN 50 mg IV q24h
• Preferred regimen (2): Micafungin 100 mg IV q24h
• Preferred regimen (3): Anidulafungin 200 mg IV single dose THEN 100 mg IV q24h

• Preferred regimen (4): Fluconazole 400–600 mg IV q24h
• Alternative regimen: Amphotericin B, Liposomal 3-5 mg/kg IV q24h

• 3. Uncommon pathogens

• 3.1 Corynebacterium jeikeium

• Preferred regimen: Vancomycin 15 mg/kg q12h (trough levels 15-20 mcg/ml)
• Alternative regimen: Linezolid 600 mg IV q12h
• Note: No clinical studies available for Linezolid. Recommendation based on in vitro activity.

• 3.2 Chryseobacterium (Flavobacterium) spp.

• Preferred regimen: Levofloxacin 750 mg IV q24h
• Alternative regimen: Trimethoprim-Sulfamethoxazole 3–5 PO/IV mg/kg q8h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h

• 3.3 Ochrobacterium anthropi

• Preferred regimen: Trimethoprim-Sulfamethoxazole 3–5 PO/IV mg/kg q8h OR Ciprofloxacin 400 mg IV q8-12h
• Alternative regimen: (Ertapenem 1 g IV/IM q24h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h OR Doripenem 500 mg IV q8h) AND Gentamicin 1 mg/kg IV q8h

• 3.4 Malassezia furfur

• Preferred regimen: Amphotericin B, Liposomal 3-5 mg/kg IV q24h
• Alternative regimen: Voriconazole 6 mg/kg IV q12h for first 24h THEN 4 mg/kg IV q12h

References

Template:WikiDoc Sources